The Final product of The Sinovac coVID-19 vaccine will arrive in Brazil this week, the Institute said. Sao Paulo state government



Instituto Butantan said Thursday that the first batch of the CoronaVac vaccine, developed by Sinovac, will arrive in Brazil this week, and the next batch of the raw materials for the vaccine produced by Sinovac should arrive by the end of November.



Dimas Covas, director of the Butantan Institute, said there would be 46 million doses of the vaccine by January, the El Pais newspaper Pernambuco reported. "We will receive the vaccine this week. We will receive the first batch of finished vaccines from China and we will also receive the first 600 litres of raw materials for the vaccine later this month for production at the Butani Institute. Everything is ongoing, so we will have 46 million doses available very soon in January." He said.



Joao Doria, the governor of Sao Paulo state, said in an interview that the finished Chinese vaccine should arrive by November 19. "The vaccine is a finished product from Sinovac and then we will produce it in Butantin so that it can be used by Sao Paulo state and all Brazilians, provided that the Ministry of Health understands, and should understand, that the vaccine is for everyone." Doria said.



The Third phase of the Coronavac test is being carried out in Brazil in cooperation between Beijing Kexin Vitalics Technology Co., Ltd. and the Butant Institute. At least 10,000 volunteers have received at least one dose of coVID-19 or a placebo.



Last week, Brazil's national health watchdog, Anvisa, briefly suspended phase iii trials of the vaccine before resuming it after confirming that the death of a volunteer was unrelated to the vaccine. The CoronaVac vaccine was safe, with an immune response in 97 percent of subjects after 28 days of vaccination, according to the study published Thursday in the Lancet Infectious Disease journal. The paper evaluated the results of phase I and phase II clinical trials of the vaccine in China.